الفرق بين المراجعتين لصفحة: «قالب:عوامل العلاج الكيميائي خارج الخلوية»
اذهب إلى التنقل
اذهب إلى البحث
(نقل مع رابط للقالب الإنكليزي) |
كنان الطرح (نقاش | مساهمات) ط (نقل كنان الطرح صفحة قالب:أدوية العلاج الكيميائي خارج الخلوي إلى قالب:عوامل العلاج الكيميائي خارج الخلوية) |
||
| (5 مراجعات متوسطة بواسطة مستخدمين اثنين آخرين غير معروضة) | |||
| سطر 1: | سطر 1: | ||
{{Navbox | {{Navbox | ||
| name = Extracellular chemotherapeutic agents | | name = Extracellular chemotherapeutic agents | ||
| title = | | title = [[Targeted therapy]] / extracellular [[Chemotherapy (oncology)|chemotherapeutic agents]]/[[Antineoplastic|antineoplastic agents]] ([[ATC code L01|L01]]) | ||
| state = {{{state|autocollapse}}} | |||
[[Targeted therapy]] / extracellular [[Chemotherapy (oncology)|chemotherapeutic agents]]/[[Antineoplastic|antineoplastic agents]] [[ATC code L01|L01]] | |||
|listclass = hlist | |listclass = hlist | ||
| groupstyle = background-color: #E5BFE5 | | groupstyle = background-color: #E5BFE5 | ||
| سطر 17: | سطر 15: | ||
* [[ErbB]]: ''[[Epidermal growth factor receptor|HER1/EGFR]]'' ([[Cetuximab]] | * [[ErbB]]: ''[[Epidermal growth factor receptor|HER1/EGFR]]'' ([[Cetuximab]] | ||
* [[Panitumumab]]) | * [[Panitumumab]]) | ||
* ''[[HER2/neu]]'' ([[Trastuzumab]]) | * ''[[HER2/neu]]'' ([[Trastuzumab]] | ||
* [[Trastuzumab emtansine]]) | |||
| group2 = Others for solid tumors | | group2 = Others for solid tumors | ||
| سطر 50: | سطر 49: | ||
* [[RTK class III]]: ''[[CD117|C-kit]] and [[Platelet-derived growth factor receptor|PDGFR]]'' ([[Axitinib]] | * [[RTK class III]]: ''[[CD117|C-kit]] and [[Platelet-derived growth factor receptor|PDGFR]]'' ([[Axitinib]] | ||
* [[Masitinib]] | |||
* [[Pazopanib]] | * [[Pazopanib]] | ||
* [[Sunitinib]] | * [[Sunitinib]] | ||
| سطر 68: | سطر 68: | ||
| group2 = [[Non-receptor tyrosine kinase|Non-receptor]] | | group2 = [[Non-receptor tyrosine kinase|Non-receptor]] | ||
| list2 = | | list2 = | ||
* ''[[Bcr-abl fusion protein|bcr-abl]]'' ([[Dasatinib]] | * ''[[Bcr-abl fusion protein|bcr-abl]]'' ([[Imatinib]] | ||
* [[ | * [[Dasatinib]] | ||
* [[ | * [[Nilotinib]] | ||
* [[Ponatinib]]) | |||
*''[[Src (gene)|Src]]'' ([[Bosutinib]]) | *''[[Src (gene)|Src]]'' ([[Bosutinib]]) | ||
| سطر 79: | سطر 80: | ||
''[[EML4]]-[[Anaplastic lymphoma kinase|ALK]]'' ([[Crizotinib]]) | ''[[EML4]]-[[Anaplastic lymphoma kinase|ALK]]'' ([[Crizotinib]]) | ||
RET inhibitors: Vandetanib (Also VEGFR and EGFR). | ''RET inhibitors:'' [[Vandetanib]] (Also VEGFR and EGFR). | ||
c-MET inhibitor: Cabozantinib (Also VEGFR2). | ''c-MET inhibitor:'' [[Cabozantinib]] (Also VEGFR2). | ||
}} | }} | ||
| group4 = | | group4 = Other | ||
| list4 = | | list4 = | ||
* ''[[fusion protein]] against [[Vascular endothelial growth factor|VEGF]]'' ([[Aflibercept]]) | * ''[[fusion protein]] against [[Vascular endothelial growth factor|VEGF]]'' ([[Aflibercept]]) | ||
| سطر 90: | سطر 91: | ||
* ''[[mTOR inhibitor]]s'' ([[Everolimus]] | * ''[[mTOR inhibitor]]s'' ([[Everolimus]] | ||
* [[Temsirolimus]]) | * [[Temsirolimus]]) | ||
| belowstyle = background: transparent; padding: 0px; | |||
| below = {{Neoplasia navs}} | |||
}}<noinclude> | }}<noinclude> | ||
[[تصنيف:جداول تصفح الأدوية]] | [[تصنيف:جداول تصفح الأدوية]] | ||
</noinclude> | </noinclude> | ||